Several investment firms have made significant adjustments to their holdings in Regeneron Pharmaceuticals, Inc. (REGN). Notably, Marshall Wace LLP, First Trust Advisors LP, BMO Capital, and Canaccord Genuity Group continue to express positive outlooks on REGN, citing opportunities for value appreciation and strong price forecasts. More companies like Invesco Ltd, Sepio Capital LP, Distillate Capital Partners, and Candriam S.C.A. have grown or established positions in the company.
However, some firms like New York State Common Retirement Fund, and American Century Companies Inc. have decreased their investments, and Morgan Stanley downgraded their rating for REGN to 'Equal Weight'. Some bearish takes have questioned Regeneron’s anemic earnings and valuation after recent FDA approvals.
Despite some pullbacks, the company sees promising prospects after announcing positive results from several late-stage trials, gaining FDA approval for EYLEA HD for a new indication, and investing $150 million in Tessera Therapeutics to advance a one-time gene therapy for a rare genetic disorder. Regeneron also touts successful phase 3 Garetosmab trials for a rare disease and has advanced its allergy pipeline with two positive Phase 3 Trials. These developments contributed to a period of share price rally, drawing attention to the firm’s resilience and potential.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 07 Aug 2025 07:00:00 GMT to Sat, 06 Dec 2025 11:51:47 GMT - Rating 7 - Innovation 5 - Information 8 - Rumor -2
